Compare PBHC & ANIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PBHC | ANIX |
|---|---|---|
| Founded | 1859 | 1982 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 101.1M | 114.0M |
| IPO Year | 2014 | 2013 |
| Metric | PBHC | ANIX |
|---|---|---|
| Price | $17.11 | $2.65 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $8.67 |
| AVG Volume (30 Days) | 3.8K | ★ 325.0K |
| Earning Date | 04-29-2026 | 05-27-2026 |
| Dividend Yield | ★ 2.94% | N/A |
| EPS Growth | ★ 46.25 | 12.82 |
| EPS | ★ 0.47 | N/A |
| Revenue | N/A | ★ $210,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $36.40 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.06 | $2.32 |
| 52 Week High | $18.30 | $5.46 |
| Indicator | PBHC | ANIX |
|---|---|---|
| Relative Strength Index (RSI) | 61.11 | 28.15 |
| Support Level | $15.48 | $2.37 |
| Resistance Level | N/A | $3.09 |
| Average True Range (ATR) | 0.42 | 0.21 |
| MACD | 0.14 | -0.07 |
| Stochastic Oscillator | 58.54 | 2.75 |
Pathfinder Bancorp Inc is a holding company for Pathfinder Bank. The Pathfinder Bank is a commercial bank engaged in attracting deposits from the general public and investing such deposits, together with other sources of funds, in loans secured by residential real estate, commercial real estate, small business loans, and consumer loans. The bank invests a portion of its assets in debt securities issued by the United States Government and its agencies and sponsored enterprises, state and municipal obligations, corporate debt securities, mutual funds, and equity securities. The principal source of income is interest on loans and investment securities.
Anixa Biosciences Inc is a biotechnology company developing therapies and vaccines focused on critical unmet needs in oncology. Its operations are organized into reportable segments comprising Cancer Vaccines, CAR-T Therapies, and Other. The Cancer Vaccines segment involves vaccines to treat and prevent breast and ovarian cancer, as well as additional cancer vaccines targeting intractable cancers, including high-incidence malignancies in lung, colon, and prostate. The CAR-T Therapies segment involves the development of liraltagene autoleucel (lira-cel), an ovarian cancer immunotherapy using chimeric endocrine receptor-T cell technology, developed at its subsidiary, Certainty Therapeutics, Inc. The Other segment consists of legacy operations, including limited patent licensing activities.